MedTrace Logo

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

NCT05510323 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2024-05-06

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.

Conditions

  • Glomerulonephritis, IGA

Interventions

DRUG

Prednisolone

RAS blockade as much as tolerated or allowed

DRUG

Prednisolone plus Cyclophosphamide

RAS blockade as much as tolerated or allowed

Sponsors & Collaborators

  • Air Force Military Medical University, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-08-31
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510323 on ClinicalTrials.gov